Efficacy of the STC-1010 a new allogenic cancer vaccine in different colorectal cancer models
F. Ghiringhelli et al, Cancer Res 2024
https://doi.org/10.1158/1538-7445.AM2024-5003 Link to Poster
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
